<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2C0AE1A4-B497-4343-8EE8-FD98C852AC55"><gtr:id>2C0AE1A4-B497-4343-8EE8-FD98C852AC55</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:surname>Morris</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B6853047-0FD9-4830-AAD5-89D341EC087C"><gtr:id>B6853047-0FD9-4830-AAD5-89D341EC087C</gtr:id><gtr:firstName>Hans</gtr:firstName><gtr:surname>Stauss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701703"><gtr:id>644662DD-8EE2-4A77-82F2-24DBD79B1B87</gtr:id><gtr:title>CMV TCR Gene Therapy: A Phase I/II Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy in Allo-HSCT</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701703</gtr:grantReference><gtr:abstractText>Patients with cancers of the blood and bone marrow are often given a form of treatment called a stem cell (or bone marrow) transplant. During the transplant procedure the patient will be given potent chemotherapy and/or radiotherapy to kill off residual cancer cells before the new stem cells are re-infused from the bone marrow donor, often a sibling. In order for the new stem cells to persist in the patient, powerful drugs need to be given to suppress the patient?s own immune system. The period of profound immune suppression can last for up to 6 months post transplant. During this time the reactivation of viruses, such as cytomegalovirus (CMV) is very common. CMV reactivation in immunosuppressed patients can lead to progressive infection and even death. In healthy individuals CMV rarely causes any problems as the T cells of the immune system are able to keep the virus in check. Individuals who have previously been infected with CMV (50% UK adults) have small numbers of T cells in their blood which can recognise and kill CMV-infected cells. Recently, researchers in the UK and Europe have shown that these CMV-specific T cells taken from bone marrow donors can be infused into the transplant patient and control CMV infection in the patient. Typically, a single infusion of the donor?s T cells is effective. This approach avoids the need for repeated anti-viral drugs, which have significant side effects and usually require the patient to be re-admitted to hospital for prolonged periods. 
However, many patients have transplant donors who have not been previously infected with CMV. These donors will not have any pre-made immune T cells which can recognise CMV. We propose to take the T cells of CMV negative donors and genetically modify them so that they are able to recognise and kill CMV-infected cells. This will be done by growing the donor T cells in the laboratory in the presence of a specially modified virus called a retroviral vector. This procedure will transfer a gene to the T cells, which allows them to recognize protein fragments (peptides) of the CMV virus called CMV pp65. The gene transferred to the T cells enables them to make a new T cell receptor (CMV TCR), which specifically recognises the CMV pp65 peptide. The CMV TCR gene-modified T cells will be infused into the patient if they reactivate CMV as part of this Phase I/II clinical trial.</gtr:abstractText><gtr:technicalSummary>The proposed Phase I/II proof of concept pilot study will test the feasibility of generating donor-derived CMV-specific T cells via the ex vivo introduction of a CMV-specific T cell receptor using a GMP grade retroviral vector. It will also determine the safety, toxicity and efficacy of CMV TCR-transduced T cells used for the pre-emptive treatment of CMV reactivation following HLA-matched sibling allogeneic haematopoietic stem cell transplantation (Allo-HSCT).
Reactivation of the latent human herpes virus, Cytomegalovirus (CMV) post allogeneic haematopoietic stem cell transplantation (Allo-HSCT) can result in significant morbidity and mortality unless treated promptly. Anti-viral therapy is usually effective, but has serious side effects, such as myelosuppression (Ganciclovir) or nephrotoxicity (Foscarnet). Cellular immunotherapy for CMV has been tested in Phase I/II trials in the UK and Europe. In these trials CMV-specific T cells were isolated from the peripheral blood of CMV seropositive donors and re-infused into recipients following CMV reactivation resulting in sustained anti-viral responses. Transplant recipients with CMV seronegative donors cannot benefit from currently available cellular immunotherapy approaches due to the lack of CMV-specific memory T cells in these donors. At present, there is no reliable strategy to isolate virus specific T cells from uninfected na?ve individuals, as the precursor frequency is low or absent and the in vitro priming of T-cell responses is inefficient. T-cell receptor (TCR) gene transfer offers a strategy to produce antigen-specific T cells independent of precursor frequency and without the need for T-cell priming. We propose that CMV TCR-transduced T cells, generated from CMV-seronegative donors, can generate protective CMV immunity in post-transplant patients.</gtr:technicalSummary><gtr:fund><gtr:end>2018-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>299213</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Birmingham Early Phase Clinical Haematology Trials Unit</gtr:description><gtr:id>48231F56-6FB4-45EC-A9A1-97709DC83D3F</gtr:id><gtr:impact>Clinical study funded by current MRC grant is in set-up. GTAC approval granted. MHRA submission pending.

Previous LLR-funded trial with Birmingham has completed.</gtr:impact><gtr:outcomeId>XSe31R8pHdu-1</gtr:outcomeId><gtr:partnerContribution>Early Phase Clinical trial support and set-up.</gtr:partnerContribution><gtr:piContribution>We have worked closely with Birmingham to set up multi-centre Phase I clinical trials of T cell immunotherapy in Haematology patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Immunology</gtr:department><gtr:description>Great Ormond Street Hospital Gene Therapy Laboratory</gtr:description><gtr:id>2DAC0F83-8CE1-4739-9620-C59C2F0ED2A9</gtr:id><gtr:impact>Generation of Clinical grade CMV TCR gene-modified T cells for use in the clinical trial funded by the current MRC grant.</gtr:impact><gtr:outcomeId>byhThBHFeTm-1</gtr:outcomeId><gtr:partnerContribution>We have collaborated to establish an MHRA-approved ATMP manufacturing facility to generate genetically modified T cells for clinical trials</gtr:partnerContribution><gtr:piContribution>We have generated protocols for the clincal scale production of genetically modified T cells for clinical use. We have prepared regualtory paperwork. We have provided research staff to work in the GOSH Gene Therapy Lab</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Centre for Cell, Gene and Tissue Therapeutics, Royal Free London Hospital NHS Trust</gtr:description><gtr:id>8B5F81F0-9E0E-4C7D-8C98-443BF2A060F0</gtr:id><gtr:impact>1. Staff trained in using Prodigy closed system for gene modification of immune cells
2. Improved manufacturing process for gene modified T cells submitted as a substantial amendment and approved by MHRA and NRES</gtr:impact><gtr:outcomeId>58ca5a78658403.19160358-1</gtr:outcomeId><gtr:partnerContribution>GMP manufacture of therapeutic T cells has been optimised and moved to the CCGTT. 
Staff have been trained in using different equipment, including the Prodigy system.
Amendments to the manufacturing process have been validated and submitted to MHRA and NRES for approval which have been received.
One member of my research team is now acting QC manager for the unit to support its exapnsion of activity.</gtr:partnerContribution><gtr:piContribution>My team and I have negotiated a move from GOSH to the CCGTT for the manufacture of GMP-modified T cells for this trial.
Intellectual input and technical support.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>DOH/GTAC schools visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>E177A1C9-51A3-41F6-94B9-03FF44E8ECD0</gtr:id><gtr:impact>Explaining genetically modified T cells for immune therapies and answering questions/concerns about gene therapy

Nuffield Foundation Summer student hosted in my lab</gtr:impact><gtr:outcomeId>504770703FA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department of Health Gene Therapy Workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AAA1BE4D-15FB-47EA-977A-9A156A1D1876</gtr:id><gtr:impact>Attended by policy makers and recorded for Secretary of State for Health and Health Minister. Aimed to reinforce requiremnet for investment in gene therapy in the UK.

Have been invited to discussion meetings with MHRA subsequently.</gtr:impact><gtr:outcomeId>gwmrnAD86oX</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Graveney Project</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E59E549F-88FB-45D3-80F3-1ED91805BF43</gtr:id><gtr:impact>I have started a project with 20 year 11 students, to perform experiments on gene-engineering in their classroom. I attend every fortnight. We have secured funding to pay for teacher time and equipment/consumables. Students are designing primers, perfomring PCR etc.</gtr:impact><gtr:outcomeId>58ca6228289171.08044585</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LRF Annual Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>DF2187D5-71D4-4752-BBDD-03F9BB04358B</gtr:id><gtr:impact>Fundraisers, patients and public attending open day to hear about research in department. Lay talks given to explain basic science research and experimental clinical trials. Also included description of MRC funded research.

Letters from patients and public.</gtr:impact><gtr:outcomeId>85093B01500</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>CCE714D4-1448-4755-B3EA-880B8CEE74D8</gtr:id><gtr:impact>500 pupils attended a special assembly led by myself on science, medicine and experimental medicine. MAny questions and much interaction.

Repeat visit requested and more detailed talks to senior classes requested.</gtr:impact><gtr:outcomeId>n3CRBzkBfPL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>245000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C24669E9-0B67-4A53-A558-FF0F8E0377AA</gtr:id><gtr:outcomeId>UMpVqEJNnHY0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>253094</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Training Fellowship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DEB890BA-E3A1-431F-B911-A3B50CF4FED7</gtr:id><gtr:outcomeId>7BBC9F480E90</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on UK policy</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>36AF57AF-4C09-4250-A603-B5EE6F61B2E5</gtr:id><gtr:impact>DOH/GTAC/MHRA workshop to discuss impact of genetics white paper and discuss future cell and gene therapy strategy. Minutes taken for the purposes of providing advice to Ministers.</gtr:impact><gtr:outcomeId>DE68CAA49A0</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>GMP grade retroviral vector encoding the TCR alpha and beta chain genes for a human CMV-specific T cell receptor (TCR) has been generated and tested in clinical GMP scale ups in preparation for the early phase clinical trial.</gtr:description><gtr:id>4316C93F-2EFA-4321-B755-B40CFB274689</gtr:id><gtr:impact>Granted full GTAC approval July 2010, which allows us to proceed to first in man clinical trial.</gtr:impact><gtr:outcomeId>BF8F8030C68</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GMP grade retroviral vector</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An assay has been developed to determine the endpoint 'persistence of TCR-transduced T cells' where FACs analysis of peripheral is insufficiently sensitive.</gtr:description><gtr:id>1BC43A19-1DBC-4CA0-B6F1-C2C74014B334</gtr:id><gtr:impact>required to interpret clinical trial data</gtr:impact><gtr:outcomeId>kLHfNuiCQzk</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RT-PCR for the detection of genetically modified T cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Our collaborators at GOSH have (with our help and in order to deliver the MRC-funded funded c;inical trial) secured and MHRA manufacturing license to produce clinicala grade genetically modified T cells for use in clinical trials. This has required the development of a specific quality system, referurbishment of new labs and training of staff, including those from our research group.</gtr:description><gtr:id>254AC12D-7D02-4828-9DF3-C13956C1AA97</gtr:id><gtr:impact>This infrastructure development was a pre-requisite to carry out the MRC-funded clinical trial. The facility is also available to others on a collaborative basis.</gtr:impact><gtr:outcomeId>Kt3hZvujyCY</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MHRA-approved ATMP Manufacturing process</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>70EB40C3-7883-44A5-B83E-82A072E0CDC3</gtr:id><gtr:title>Optimizing T-cell receptor gene therapy for hematologic malignancies.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9b9c87b0bc511b71ba865da0f5ad2ff"><gtr:id>a9b9c87b0bc511b71ba865da0f5ad2ff</gtr:id><gtr:otherNames>Morris EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58ca5ee21b5f89.22196964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DF03F5D-AC02-402E-AB12-114F5A51BA29</gtr:id><gtr:title>Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fddbee7fc8ebee4cdd6e609fe63ce53"><gtr:id>6fddbee7fc8ebee4cdd6e609fe63ce53</gtr:id><gtr:otherNames>Holler A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>56e04e7be4db50.14588136</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701703</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>11</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>11</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>986F1CAE-CC43-4D59-8F85-A91971E4C4BE</gtr:id><gtr:percentage>11</gtr:percentage><gtr:text>Other</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>